Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 971 of 6351
-
New drug combo shows promise for Hard-to-Treat sarcomas
Disease control OngoingThe purpose of this study is to find out whether combining the study drugs, lenvatinib and pembrolizumab, is a safe and effective treatment for metastatic soft tissue sarcomas that cannot be removed with surgery.
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Gene therapy for hemophilia b shows promise in Long-Term study
Disease control CompletedThis is an open-label, extension study enrolling patients who have successfully completed all assessments in Study CT-AMT-060-01 (Years 1-5). Assessment phase will begin at Visit 36 (the first clinical visit in this extension study, approximately 5.5 years after the initial dosin…
Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
MRI-Guided radiation boosts hopes for rectal cancer patients
Disease control Recruiting nowNeoadjuvant chemoradiation therapy (nCRT) is the standard treatment modality for locally advanced rectal cancer (LARC), and patients achieving complete response (CR) generally have improved local control, metastasis-free survival, and overall survival. The aim of this clinical t…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New hope for kids with severe colitis: drug shows promise in major trial
Disease control CompletedThe purpose of this study is to evaluate: a) the efficacy of ustekinumab dosing in inducing clinical remission, b) safety profile of ustekinumab, and c) ustekinumab exposure (pharmacokinetics \[PK\]) in pediatric participants with moderately to severely active UC.
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug cocktail may make inoperable liver cancer removable
Disease control CompletedThe study is being conducted to evaluate the efficacy and safety of conversion treatment of Hepatic Arterial Infusion Chemotherapy combined with Camrelizumab and Apatinib for unresected hepatocellular carcinoma.
Phase 2 • Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Adaptive chemo strategy aims to get more pancreatic cancer patients to surgery
Disease control OngoingThe purpose of this study is to determine if neoadjuvant therapy to increases resection rate for pancreatic adenocarcinoma.
Phase 2 • Sponsor: University of Cincinnati • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Double radiation attack aims to blast stubborn thyroid cancer
Disease control Recruiting nowThe goal of this study is to evaluate combined radioactive iodine (RAI, 131-I) and external beam radiotherapy (XRT) to optimize the radiation dose delivered to treat well differentiated thyroid cancers (DTC) with iodine-avid metastases. The investigators hypothesize that precise …
Phase 1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Immunotherapy boosts bladder cancer treatment, early trial shows promise
Disease control OngoingThis phase II trial studies the benefit of adding an immunotherapy drug called MEDI4736 (durvalumab) to standard chemotherapy and radiation therapy in treating bladder cancer which has spread to the lymph nodes. Drugs used in standard chemotherapy work in different ways to stop t…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New hope for myelofibrosis: selinexor trial targets spleen and symptoms
Disease control OngoingThis is a Phase 2, multicenter, two-arm, open-label study to evaluate the safety and efficacy of selinexor versus treatment per physician's choice (PC) in participants with myelofibrosis (MF) who had at least 6 months of treatment with a Janus kinase (JAK)1/2 inhibitor. Study par…
Phase 2 • Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New combo therapy shows promise for aggressive lung cancer
Disease control CompletedThe purpose of this study is to demonstrate that treatment with BMS-986012 in combination with carboplatin, etoposide, and nivolumab will have acceptable safety and tolerability and will improve progression-free survival compared with carboplatin, etoposide, and nivolumab alone i…
Phase 2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug crovalimab aims to control rare blood disorder PNH
Disease control OngoingThis study will enroll participants aged 12 years or older with a body weight ≥ 40 kilograms (kg) diagnosed with PNH who have not been previously treated with complement inhibitor therapy. Approximately 50 participants will be treated with Crovalimab for at least 24 weeks.
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New combo shows promise for rare adrenal cancers
Disease control OngoingThis phase II trial studies how well the addition of olaparib to the usual treatment, temozolomide, works in treating patients with neuroendocrine cancer (pheochromocytoma or paraganglioma) that has spread from where it first started (primary site) to other places in the body (me…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New MS pill aims to slow disability in phase 3 showdown
Disease control OngoingA study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized in a 1:1 ratio to receive either fenebrutinib or teriflunomide. At the end of the double-blind treatment…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New combo therapy aims to knock back recurrent prostate cancer
Disease control OngoingThis phase II trial studies how well antiandrogen therapy (leuprolide, apalutamide, and abiraterone acetate) and stereotactic body radiation therapy (SBRT) works in treating patients with prostate cancer that has come back and has spread to other parts of the body. Drugs used in …
Phase 2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New antibody combo shows promise for tough ovarian cancer
Disease control OngoingThis is a single arm phase 1b/2 evaluation of the combination of oregovomab, and bevacizumab, paclitaxel carboplatin in adult subjects with CA125-associated, advanced recurrent epithelial ovarian, fallopian tube or peritoneal carcinoma (FIGO Stage III/IV) with BRCA-wild type, pre…
Phase 1/2 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Weekly shot eases heart failure symptoms in obese patients, study shows
Symptom relief CompletedThis study will look at how the participants daily life is affected by their heart failure. The study will also look at the change in participants body weight from the start to the end of the study. This is to compare the effect on heart failure symptoms and on body weight in peo…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Symptom relief
Last updated Jun 27, 2026 08:02 UTC
-
New Alzheimer's drug aims to clear brain plaques
Disease control OngoingThe purpose of this study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of multiple-ascending intravenous (IV) doses of RO7126209 in participants with prodromal or mild to moderate Alzheimer's disease (AD), who are amyloid positiv…
Phase 1/2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail targets hard-to-treat breast cancer
Disease control OngoingImmune checkpoint inhibitors given in monotherapy in advanced breast cancer have shown modest benefit in first-line, but very limited efficacy in later lines. Thus, combination therapies are needed. Response following anti-PD1/PD-L1 monotherapy is associated with large survival …
Phase 2 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Disease control
Last updated Jun 26, 2026 15:16 UTC
-
Custom-Made stent grafts offer hope for High-Risk aneurysm patients
Disease control Recruiting nowThe primary objective of this study is to examine the safety and effectiveness of physician-modified endovascular grafts (PMEGs) for endovascular repair of complex aortic pathology in high-risk patients. The study is divided into three study arms based on the subject's aortic pat…
Sponsor: Beth Israel Deaconess Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New device offers hope for heart and lung patients
Disease control Recruiting nowThis prospective study is a multi-center early feasibility study assessing the safety and performance of the Aria CV Pulmonary Hypertension System in patients with pulmonary hypertension and right heart dysfunction.
Sponsor: Aria CV, Inc • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC